---
title: "Absci Corporation (ABSI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABSI.US.md"
symbol: "ABSI.US"
name: "Absci Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T12:01:01.075Z"
locales:
  - [en](https://longbridge.com/en/quote/ABSI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABSI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABSI.US.md)
---

# Absci Corporation (ABSI.US)

## Company Overview

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.absci.com](https://www.absci.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.72)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 229 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -61.87% |  |
| Net Profit YoY | -10.20% |  |
| P/B Ratio | 4.20 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 721840409.28 |  |
| Revenue | 1836000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -63.89% | E |
| Profit Margin | -6450.76% | E |
| Gross Margin | -8865.12% | E |
| Revenue YoY | -61.87% | E |
| Net Profit YoY | -10.20% | D |
| Total Assets YoY | -15.85% | E |
| Net Assets YoY | -13.49% | E |
| Cash Flow Margin | 82.23% | C |
| OCF YoY | -61.87% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 12.08% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Absci Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-61.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "721840409.28",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1836000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-63.89%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-6450.76%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-8865.12%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-61.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.20%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.85%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-13.49%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "82.23%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-61.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.08%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.09 | 399/386 | - | - | - |
| PB | 4.20 | 304/386 | 2.86 | 2.22 | 1.86 |
| PS (TTM) | 393.16 | 281/386 | 178.95 | 143.96 | 86.72 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 2 | 22% |
| Hold | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.63 |
| Highest Target | 12.00 |
| Lowest Target | 4.10 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABSI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABSI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABSI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABSI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**